Advertisement
GOSS vs NXTC
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GOSS is a Hold and NXTC is a Hold.
GOSS's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for GOSS turned positive on October 12, 2026. Looking at past instances where GOSS's MACD turned positive, the stock continued to rise in 34 of 38 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on GOSS as a result. In 70 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.
Following a +9.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where GOSS advanced for three days, in 214 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GOSS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
GOSS broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GOSS entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.636) is normal, around the industry mean (3.498). P/E Ratio (-0.230) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.666) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. GOSS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GOSS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Aroon Indicator for NXTC shows an upward move is likely
NXTC's Aroon Indicator triggered a bullish signal on October 21, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 101 similar instances where the Aroon Indicator showed a similar pattern. In 94 of the 101 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for NXTC just turned positive on November 09, 2026. Looking at past instances where NXTC's MACD turned positive, the stock continued to rise in 35 of 45 cases over the following month. The odds of a continued upward trend are 78%.
Following a +22.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where NXTC advanced for three days, in 189 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The 10-day RSI Indicator for NXTC moved out of overbought territory on October 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 24 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 50 cases where NXTC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NXTC as a result. In 74 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
NXTC moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NXTC crossed bearishly below the 50-day moving average on October 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NXTC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
NXTC broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.008) is normal, around the industry mean (3.498). P/E Ratio (-0.644) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. NXTC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NXTC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
GOSS | NXTC | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 30 | 20 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 33 Fair valued | 64 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 64 | 79 | |
P/E GROWTH RATING 1..100 | 28 | 43 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GOSS's Valuation (33) in the Pharmaceuticals Major industry is in the same range as NXTC (64) in the Biotechnology industry. This means that GOSS’s stock grew similarly to NXTC’s over the last 12 months.
GOSS's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as NXTC (100) in the Biotechnology industry. This means that GOSS’s stock grew similarly to NXTC’s over the last 12 months.
GOSS's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as NXTC (100) in the Biotechnology industry. This means that GOSS’s stock grew similarly to NXTC’s over the last 12 months.
GOSS's Price Growth Rating (64) in the Pharmaceuticals Major industry is in the same range as NXTC (79) in the Biotechnology industry. This means that GOSS’s stock grew similarly to NXTC’s over the last 12 months.
GOSS's P/E Growth Rating (28) in the Pharmaceuticals Major industry is in the same range as NXTC (43) in the Biotechnology industry. This means that GOSS’s stock grew similarly to NXTC’s over the last 12 months.
| GOSS | NXTC | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 86% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 89% | 1 day ago 86% |
| MACD ODDS (%) | 1 day ago 89% | 1 day ago 78% |
| TrendWeek ODDS (%) | 1 day ago 85% | 1 day ago 83% |
| TrendMonth ODDS (%) | 1 day ago 86% | 1 day ago 87% |
| Advances ODDS (%) | 1 day ago 85% | 3 days ago 82% |
| Declines ODDS (%) | 9 days ago 89% | 7 days ago 86% |
| BollingerBands ODDS (%) | 1 day ago 82% | 6 days ago 82% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GOSS’s FA Score shows that 2 FA rating(s) are green while NXTC’s FA Score has 0 green FA rating(s).
- GOSS’s FA Score: 2 green, 3 red.
- NXTC’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GOSS’s TA Score shows that 3 TA indicator(s) are bullish while NXTC’s TA Score has 4 bullish TA indicator(s).
- GOSS’s TA Score: 3 bullish, 4 bearish.
- NXTC’s TA Score: 4 bullish, 6 bearish.
Price Growth
GOSS (@Biotechnology) experienced а +21.55% price change this week, while NXTC (@Biotechnology) price change was +2.22% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
GOSS is expected to report earnings on Nov 11, 2026.
NXTC is expected to report earnings on Mar 04, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
GOSS and
Correlation & Price change
A.I.dvisor indicates that over the last year, GOSS has been loosely correlated with LITS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GOSS jumps, then LITS could also see price increases.
| Ticker / NAME | Correlation To GOSS | 1D Price Change % | ||
|---|---|---|---|---|
| GOSS | 100% | +3.63% | ||
| LITS - GOSS | 46% Loosely correlated | +2.86% | ||
| APVO - GOSS | 41% Loosely correlated | -29.63% | ||
| IDYA - GOSS | 38% Loosely correlated | +3.04% | ||
| XNCR - GOSS | 38% Loosely correlated | +1.47% | ||
| SYRE - GOSS | 38% Loosely correlated | +2.24% | ||
More | ||||
NXTC and
Correlation & Price change
A.I.dvisor indicates that over the last year, NXTC has been loosely correlated with CYTK. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if NXTC jumps, then CYTK could also see price increases.
| Ticker / NAME | Correlation To NXTC | 1D Price Change % | ||
|---|---|---|---|---|
| NXTC | 100% | N/A | ||
| CYTK - NXTC | 37% Loosely correlated | +4.18% | ||
| JSPR - NXTC | 36% Loosely correlated | +0.07% | ||
| ORMP - NXTC | 33% Poorly correlated | +4.03% | ||
| GOSS - NXTC | 32% Poorly correlated | +3.63% | ||
| TAOX - NXTC | 28% Poorly correlated | -1.55% | ||
More | ||||